Eczema Trial, Recruiting NCT07544862 Sponsor: Chengdu Kangnuoxing Biopharma,Inc. Condition: Eczema
Back to Eczema

Eczema Trial, Recruiting

NCT07544862
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older, of any gender.
  • People for whom a doctor has already decided, separately from and before this study, to prescribe Stapokibart Injection for atopic dermatitis (a type of eczema), based on the prescribing guidelines used in China.

Who may not be able to join:

  • People who have had a known allergic reaction to Stapokibart Injection in the past.
  • People who are currently taking part in, or planning to take part in, another clinical trial that involves a medical treatment or intervention.
  • People who have a blood cancer or a cancer affecting the blood and bone marrow.
  • People who are pregnant.
  • People who have any other condition that, in the opinion of the trial doctor, may affect their ability to take part in the study (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 028-88610620

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Chengdu Kangnuoxing Biopharma,Inc.
Registry
ClinicalTrials.gov
Start date
2 June 2026
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The incidence rate of adverse reactions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov